Imunon submits plan in consultation with Nasdaq to ensure compliance

IMUNON (IMNN) announced that, in consultation with The Nasdaq Stock Market, it has submitted its plan to Nasdaq to regain compliance with the minimum bid price requirement and the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market. On May 29, 2025, the Company requested a hearing before The Nasdaq Hearings Panel. At this hearing, the Company will request an extension to meet the requirements and return to compliance. In an exchange with Nasdaq, the Company has established a pathway to an additional compliance period of 180 calendar days to regain compliance with the minimum bid price requirement and the minimum stockholders’ equity requirement, subject to final review by the Panel. Pursuant to Nasdaq Listing Rule 5815(a)(1)(B), the hearing request stayed the suspension of trading and delisting of the common stock pending the conclusion of the hearing process.